Beste Talking Oncology podcaster (2023)

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18

8d ago37:18

37:18

Role for definitive chemotherapy and radiation Controversy on induction chemotherapy Considerations for nasopharyngeal cancer Approach to metastatic HNSCC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by A…

T

The Cancer Pod: Integrative Oncology Talk

1
Pine: Is it Medicine? 17:49

19h ago17:49

17:49

'Tis the season! Pine trees are everywhere! From vitamin C to turpentine (yes, the paint thinner!), pine trees give us a lot to talk about. Listen in as Tina & Leah chat about the uses and cautions of the ubiquitous pine tree in this holiday minisode. And don't forget... hit those 5 stars and send this episode to someone you think would enjoy it! T…

A

All Talk Oncology Podcast

1
Youtube Coach Battles Cancer: Owen’s Unfiltered Story 1:12:05

3d ago1:12:05

1:12:05

In this episode, we engage in a powerful and insightful conversation with Owen, a YouTube coach and cancer survivor. Together, we explore Owen's inspiring journey on how faced cancer twice, he emphasizes the significance of a strong support system and discusses the emotional challenges he encountered. Throughout our discussion, we dive into themes …

O

Oncology Times - OncTimes Talk

1
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active 11:10

7d ago11:10

11:10

Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Be…

O

Oncology Times - OncTimes Talk

1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 15:23

15d ago15:23

15:23

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…

T

The Cancer Pod: Integrative Oncology Talk

1
Cranberry, A Healthy Addition to Your Plate! 20:34

15d ago20:34

20:34

It's that time of year! Cranberries are in season! There's a good chance you'll sit down to some cranberry dishes or drinks during the holidays. Maybe this episode can be fodder for conversation? ("Yes, Uncle Frank, those pics are... something. That chicken nugget really does look like Elvis. A-hem, how about this cranberry sauce? Did you know... "…

O

Oncology Times - OncTimes Talk

1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition 13:38

21d ago13:38

13:38

Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…

O

Oncology Times - OncTimes Talk

1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones 14:50

21d ago14:50

14:50

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC int…

O

Oncology Times - OncTimes Talk

1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer 15:22

21d ago15:22

15:22

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…

O

Oncology Times - OncTimes Talk

1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties 24:17

22d ago24:17

24:17

The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…

T

The Cancer Pod: Integrative Oncology Talk

1
8 Cancer Myths: From Contagions to Cures 41:27

22d ago41:27

41:27

Everyone has heard a myth or two about cancer (hello, sugar!) The American Society of Clinical Oncology (ASCO) published eight "Myths and Facts About Cancer." Some of the myths they brought up were ones we've heard from patients, others...kind of cringey. We thought we should tackle them one by one. Not surprisingly, there is often a vein of truth …

O

Oncology Times - OncTimes Talk

1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer 18:59

23d ago18:59

18:59

Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…

O

Oncology Times - OncTimes Talk

1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax 15:20

24d ago15:20

15:20

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…

A

All Talk Oncology Podcast

1
Empowerment Down Under: Meet Helen Beeley from Brisbane 48:15

24d ago48:15

48:15

In this episode, our guest, Helen Beeley, shares her remarkable journey, emphasizing the power of determination, a positive outlook, and the unwavering human spirit. Helen inspires us with her story. Her experiences serve as a beacon of hope, reminding us that with the right mindset, support, self-care, and resilience, we can overcome life's challe…

T

The Cancer Pod: Integrative Oncology Talk

1
Who's In Your Pod? Chanchal Cabrera, The Medical Herbalist 1:05:40

1M ago1:05:40

1:05:40

Herbal medicine is part of our daily lives. Coffee, tea, soup, salads... we are already consuming plants, and many are medicinal. Walking in nature and gardening, these are also aspects of plant medicine. Listen to the latest episode of The Cancer Pod, where Tina and Leah chat with Chanchal Cabrera, MSc, FNMIH, RHT, (RH) AHG , whose career as a med…

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28

1M ago23:28

23:28

Anatomy, diagnostic work-up and staging Field cancerization Indications for adjuvant concurrent chemoradiation Evidence to support weekly cisplatin with concurrent radiation Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidel…

A

All Talk Oncology Podcast

1
A Tribute to a Remarkable Soul: Jessie Lee’s Cancer Journey 56:06

1M ago56:06

56:06

In this episode, we honor the memory of Jessie Lee, in her battle with colon cancer. Her inspiring journey, filled with resilience and positivity, serves as a beacon of hope. Join us as we revisit her story and celebrate her enduring spirit. This is an episode you do not want to miss. Subscribe and share with others who may find strength and inspir…

T

The Cancer Pod: Integrative Oncology Talk

1
Who's in Your Pod? Lise Alschuler, ND, FABNO, The Naturopathic Professor 47:04

2M ago47:04

47:04

We talked with Dr. Lise Alschuler about the three most important things to reduce cancer risk and its recurrence. With almost 30 years as a clinician, as well as a cancer survivor herself, Dr. Alschuler is an authority on the topic. Join Tina & Leah in this not-to-be-missed episode. Where else will you find three naturopathic physicians giving out …

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40

2M ago29:40

29:40

Presentation, and considerations for regional mesothelioma Systemic therapy options for advanced mesothelioma Corticosteroids for pemetrexed, paclitaxel and docetaxel A quick review on considerations for LCNEC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. …

T

The Cancer Pod: Integrative Oncology Talk

1
The BMI Paradox 37:25

2M ago37:25

37:25

Does a higher BMI sometimes lead to better outcomes? Is BMI what we should be using to measure obesity? Whether you are considered obese, overweight, normal weight, or underweight... your BMI can be misleading. Tina & Leah delve into the details and give you some advice to achieve the ultimate goal: living your best life as long as you possibly can…

A

All Talk Oncology Podcast

1
A Beacon of Hope: Christine’s Inspiring Breast Cancer Survivorship 32:16

2M ago32:16

32:16

In this episode, breast cancer survivor Christine Handy shares her remarkable journey, highlighting the power of mindset, support, self-care, and resilience. Her story is a beacon of hope, reminding us that with determination and a positive outlook, we can overcome the challenges of life. Tune in for inspiration and valuable insights from Christine…

T

The Cancer Pod: Integrative Oncology Talk

1
5 Things We Wouldn't Do During Treatment 33:05

3M ago33:05

33:05

Some things supporting wellness are a great idea — if you're not in the middle of cancer treatment! Tina and Leah talk about some good-for-you, healthy, and usually risk-free things you should avoid while getting active treatment. Avoiding anything that may undermine your treatment success is a top priority, so don't miss this one! Support the show…

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_10 Small cell lung cancer 33:31

3M ago33:31

33:31

Background on SCLC Approach to treatment by stage Emerging discussion on prophylactic cranial irradiation Brief review of basket and umbrella trials Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, E…

T

The Cancer Pod: Integrative Oncology Talk

1
Updates and Breakthroughs! 49:44

3M ago49:44

49:44

Time flies! Before you know it, another year's gone by! We've hit some hot topics this past year, and the info just keeps coming! So, Tina & Leah plucked from the headlines and updated some prior episodes with the newest info. They also look to the future of cancer diagnosis (will ants someday be involved?) and tackle a listener question about mush…

A

All Talk Oncology Podcast

1
Two Battles, One Spirit: How Lauren Tarpley Conquered a Tumor and the Pandemic 40:24

3M ago40:24

40:24

Join us as we sit down with Lauren Tarpley, a resilient entrepreneur who shares her inspiring journey of overcoming a life-altering cancer diagnosis and navigating the challenges of the pandemic. Her story is one of hope, courage, and determination. For more gems and in-depth discussion, make sure to listen to the entire episode. This is an episode…

O

Oncology Times - OncTimes Talk

1
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance 11:54

3M ago11:54

11:54

Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_09 Stage III NSCLC for the Medical Oncologist 27:46

3M ago27:46

27:46

Refresher on T+N staging for Stage III Evidence for concurrent chemoradiation PACIFIC Trial Encourage cessation regardless of stage of Lung Cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESM…

T

The Cancer Pod: Integrative Oncology Talk

1
Green Tea: Supplements 101 39:35

4M ago39:35

39:35

Green tea is a hugely popular drink and supplement. But are its health claims warranted? In this episode, Tina & Leah bring you the facts about green tea's benefits. As usual, there are some unique considerations regarding cancer. So tune in to find out if this anti-oxidant-rich tea should be a high priority on your to-do list! Memorial Sloan-Kette…

O

Oncology Times - OncTimes Talk

1
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression 11:43

4M ago11:43

11:43

Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…

O

Oncology Times - OncTimes Talk

1
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer 9:17

4M ago9:17

9:17

A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_08 ADAURA Trial 25:58

4M ago25:58

25:58

Background on adjuvant EGFR therapy Discussion of initial and updated results Hazard Ratios and Context When crossover and access limit generalizability Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASC…

O

Oncology Times - OncTimes Talk

1
Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer 9:17

4M ago9:17

9:17

Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary…

T

The Cancer Pod: Integrative Oncology Talk

1
Slay Stress with Adaptogens: Supplements 101 56:54

4M ago56:54

56:54

Adaptogens are all the rage, making their way into popular pick-me-up products (looking at you, Monster energy drinks). Many different plants are adaptogens (Ashwaganda, Ginseng, Rhodiola, etc), but should these plants really be taken willy-nilly? Tina & Leah give you the low down on adaptogens, including their uses, side effects, and some contrain…

O

Oncology Times - OncTimes Talk

1
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients 8:16

4M ago8:16

8:16

A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting from an alarmingly high rate of false-negative tests coming from biopsy specimens looking for biological parameters such as PR and HER2. Study researchers at the University of Catania suggested tumor h…

A

All Talk Oncology Podcast

1
From the Spotlight to Survival: A Comedian Cancer 44:03

4M ago44:03

44:03

In this episode, we explore the incredible story of Alex Hooper, a fearless stand-up comedian who bravely battled and conquered Lymphoma. Prepare to be captivated by his tales of unwavering resilience, humor, and triumph as he navigated from the spotlight of the stage to the ultimate battle for survival. For more gems and in-depth discussion, make …

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_07 (Neo)Adjuvant NSCLC 24:16

4M ago24:16

24:16

Considerations with surgery, radiation, rate of relapse Adjuvant chemotherapy Adjuvant immune checkpoint inhibition Emerging neoadjuvant trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO an…

T

The Cancer Pod: Integrative Oncology Talk

1
Diarrhea Revisited 44:28

4M ago44:28

44:28

This isn't a sexy topic but darn it, someone has to talk about it! We naturopathic doctors don't shy away from sh*t talk. In fact, we encourage it! We're rereleasing this episode because there's a slew of newer oral agents that cause loose stool and/or diarrhea. Listen in as Tina and Leah help you understand how it happens and what you can do about…

O

Oncology Times - OncTimes Talk

1
Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer 3:42

4M ago3:42

3:42

Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting. OncTimesTalk correspondent Peter Goodwin discusses the findi…

O

Oncology Times - OncTimes Talk

1
Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer 14:17

5M ago14:17

14:17

Being overweight or obese can reduce the benefit of extending adjuvant breast cancer hormone therapy in women younger than 60 years, according to research from the DATA trial discussed at the European Society for Medical Oncology (ESMO) Breast Cancer 2023 Congress. Senna W.M. Lammers, MD, from Maastricht University Medical Centre in The Netherlands…

A

All Talk Oncology Podcast

1
Cancer and Cuisine: Unveiling the Power of Nutrition 35:01

5M ago35:01

35:01

In this episode, we invited Nichole Andrews, a Cancer Dietitian Nutritionist, who shared invaluable insights for those who are battling cancer. Nichole highlighted the significance of adapting food options to suit individual tastes, as they undergo significant changes during their cancer treatment. While acknowledging the absence of one-size-fits-a…

T

The Cancer Pod: Integrative Oncology Talk

1
The Truth About...Repurposed Drugs to Treat Cancer 52:28

5M ago52:28

52:28

Drug repurposing is using a drug previously approved for one condition to treat an entirely different condition (like cancer). In cancer care, repurposed drugs are usually gentler than FDA-approved cancer treatments. They include common drugs for diabetes, high blood pressure, infections, and more. Tina & Leah talk about who should consider this st…

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_06 Driver Mutations in Advanced NSCLC 34:06

5M ago34:06

34:06

EGFR inhibitors ALK inhibitors Less common molecular targets Role of KRAS inhibitors and evidence for sotorasib Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to …

O

Oncology Times - OncTimes Talk

1
ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO 11:05

5M ago11:05

11:05

Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of …

O

Oncology Times - OncTimes Talk

1
ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs 7:14

5M ago7:14

7:14

End-of-life care for patients with cancer could be significantly improved while simultaneously reducing cost according to the findings of a study from the University of Pennsylvania. Ravi Parikh, MD, MPH, talks with OncTimesTalk correspondent Peter Goodwin about his findings on the value of harnessing AI to help doctors have serious illness convers…

T

The Cancer Pod: Integrative Oncology Talk

1
The Truth About Detox and Cleansing 58:06

5M ago58:06

58:06

Detox programs are popping up everywhere, but what’s the best approach? Do you really need to chug charcoal?! Tina & Leah talk about what detox means from their perspectives. And while they agree on most of it, they each bring a different perspective on how detoxification, elimination, and cleansing should be defined. Tune in to learn more! Harvard…

O

Oncology Times - OncTimes Talk

1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD 5:30

5M ago5:30

5:30

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…

A

All Talk Oncology Podcast

1
Whispers of Strength: Head And Neck Cancer Survivor’s Story 36:50

5M ago36:50

36:50

In this episode, Kenneth Jackson shares his courageous battle, the challenges he faced, and the triumphs he celebrated along the way. From the darkest moments to the brightest victories, his story will leave you inspired and uplifted. Tune in now on your favorite podcast platform to listen to "Whispers of Strength: Head And Neck Cancer Survivor's S…

O

Oncology Times - OncTimes Talk

1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD 11:04

6M ago11:04

11:04

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…

T

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1
03_05 NSCLC metastatic without driver mutations 31:52

6M ago31:52

31:52

Evidence to support platinum doublets The tale of pemetrexed Immune checkpoint inhibitors alone and in combination Second Line, approach in progression Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO…

T

The Cancer Pod: Integrative Oncology Talk

1
Integrative Approaches to Pain Control 58:31

6M ago58:31

58:31

Did you know you can lower pain levels with natural agents as well as medications? Food matters too. What you eat can worsen pain, while some foods help you resolve it. Tina & Leah are naturopathic doctors who know what works (and what doesn’t!). They’ll spare you the arms-length list of supplements that “may” help. So tune in and find out how to l…

Podcaster verdt å lytte til

Talking Oncology Podcaster

Podcaster verdt å lytte til

Hurtigreferanseguide